In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide Gonadorelin (GnRH, LHRH) | Synthetic analog Triptorelin (Trelstar, Decapeptyl) | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Synthetic analog | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 115 | 1,338 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 9 (9 in people) | 164 (160 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 14 · 4 active4 more mention it but do not test it | 207 · 44 active104 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Gonadorelin (GnRH, LHRH) | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual health | 8989 | 78259917112 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
The FDA label for Trelstar says: “Treatment of advanced prostate cancer”
| Adverse eventsWhole body |
|---|
99 |
105105 |
| Bone and jointMusculoskeletal | 33 | 74713 |
|---|
| Receptor activity and mechanismNervous system and cognition | 77 | 7425715 |
|---|
| Body weightMetabolic and weight | 11 | 17161 |
|---|
| PharmacokineticsPharmacology | 11 | 19136 |
|---|
| LipidsMetabolic and weight | 11 | 981 |
|---|
| Glycemic controlMetabolic and weight | 22 | 33 |
|---|
| Appetite and food intakeEndocrine and hormones | 22 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Triptorelin (Trelstar, Decapeptyl) differs from Gonadorelin at 2 positions and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Gonadorelin (GnRH, LHRH) | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Sex hormones and fertilityEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | No comparable result 10 randomized-trial results measure it in another way or another unit. | 22.7% Pregnancy rate Placebo: 22.1% Dose studied: 0.1 mgSingle injectionn = 3442010 |
| Adverse eventsReproductive and sexual healthCompared as: difference from placebo, in percentage points | No randomized trial result 9 results from other study designs. | −14.7 percentage points Miscarriage rate reduction · Shown as a change. The study reports a miscarriage rate reduction of this size. Dose studied: 0.1 mg, single dosen = 1442018 |
| Bone and jointEndocrine and hormonesCompared as: value in the arm that got the peptide, in nmol/l | No randomized trial result 3 results from other study designs. | 0.49 nmol/L Serum osteocalcin Dose studied: 3.75 mg every 28 days6 monthsn = 101994 |
No comparable result
10 randomized-trial results measure it in another way or another unit.
22.7%
Pregnancy rate
Placebo: 22.1%
Dose studied: 0.1 mgSingle injectionn = 3442010
No randomized trial result
9 results from other study designs.
−14.7 percentage points
Miscarriage rate reduction · Shown as a change. The study reports a miscarriage rate reduction of this size.
Dose studied: 0.1 mg, single dosen = 1442018
No randomized trial result
3 results from other study designs.
0.49 nmol/L
Serum osteocalcin
Dose studied: 3.75 mg every 28 days6 monthsn = 101994
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 14 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ferring Pharmaceuticals39 participants1 Apr 2014 to 23 Feb 2018
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Ferring Pharmaceuticals132 participantsFeb 2005 to Nov 2005
InFertility
RenJi Hospital78 participantsest. 1 Jul 2019 to est. 30 Dec 2021
Polycystic Ovary Syndrome · Infertility · Ovulation Disorder
4 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 207 trials, ranked by phase, then posted results and enrollment: 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
ETOP IBCSG Partners Foundation3,066 participants17 Dec 2003 to 6 Nov 2024
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma · Stage IA Breast Cancer · Stage IB Breast Cancer · Stage IIA Breast Cancer · Stage IIB Breast Cancer · Stage IIIA Breast Cancer
ETOP IBCSG Partners Foundation2,672 participants3 Nov 2003 to 23 Oct 2024
Breast Cancer
Radiation Therapy Oncology Group1,792 participantsFeb 2008 to 12 Jul 2018 (primary)
Prostate Cancer
104 more mention it but do not test it. They only measure it or name it in their text.